No Data
iFly Medical Technology (02506.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.
Gelonghui, March 14丨 iFlytek Medical Technology (02506.HK) announced that the Board of Directors will hold a meeting on March 26, 2025 (Wednesday) to consider and approve the group's annual performance for the year ending December 31, 2024, the proposed final dividend (if any), and to address other matters.
XUNFEIHEALTH: DATE OF BOARD MEETING
[Brokerage Focus] China International Capital Corporation: There is still significant room for improvement in China's Consumer market.
Gold Sentinel Financial News | The China International Capital Corporation report points out that, from multiple dimensions, the ratio of Consumer spending to GDP in China is relatively low. In international comparisons, the proportion of Commodity consumption to GDP in China does not deviate significantly from its economic development stage, but the deviation of service consumption's share of GDP from its economic development stage is more pronounced. The bank states that looking to the future, there is still significant room for improvement in China's Consumer spending, where the potential for service consumption is greater than that for Commodity consumption, especially in areas like Medical Insurance and cultural entertainment. The potential for Commodity consumption lies more in upgrading, meaning quality enhancement, while the potential for service consumption may primarily focus on increasing quantity. Raising laborers' remuneration will help boost.
iFly Medical Technology (02506) has been included in the Hong Kong Stock Connect, initiating a wave of "AI + Medical" value reassessment.
Focus on Medical Services at the grassroots level.
[Brokerage Focus] China Merchants first gives iFlytek Medical Technology (02506) a "Shareholding" rating. Rapid penetration of personal post-diagnosis services brings growth in the company's revenue capacity and sustainability.
Jinwu Financial News | China Merchants released a Research Report indicating that iFlytek Medical Technology (02506), based on a solid customer foundation on the G-side and supported by the Spark large model, surpasses the technical barriers of GPT-4Turbo in six dimensions related to medicine, making it a leader in the domestic AI Medical practice. The company's B-side smart hospital and diagnostic assistant product benchmark projects are being implemented at West China Hospital and others, expected to further expand its client base of hospitals. The C-side business is led by G and B sides, with personal post-diagnosis services rapidly penetrating in some provinces, bringing revenue growth and sustainability enhancement for the company. The report continues that, according to Zhiyan Consulting data, the scale of China's AI medical market.
Hong Kong stocks movement | iFlytek Medical Technology (02506) is currently up over 4%. Recently, the Starfire Medical Large Model X1 was released, and the company is expected to enter the Hong Kong Stock Connect list.
iFlytek Medical Technology (02506) is currently up over 4%, as of the time of writing, it has increased by 4.65%, priced at 146.3 Hong Kong dollars, with a trading volume of 19.7547 million Hong Kong dollars.
